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Background. To evaluate the current status of malaria at parturition and its impact on delivery outcome in Nigeria. Methods. A total
of 2500 mother-neonate pairs were enrolled at 4 sites over a 12-month period. Maternal and placental blood smears for malaria
parasitaemia and haematocrit were determined. Results. Of the 2500 subjects enrolled, 625 were excluded from analysis because
of breach in study protocol. The mean age of the remaining 1875 mothers was 29.0 ± 5.1 years. The prevalence of parasitaemia
was 17% and 14% in the peripheral blood and placenta of the parturient women, respectively. Peripheral blood parasitaemia was
negatively associated with increasing parity (P < .0001). Maternal age <20 years was significantly associated with both peripheral
blood and placental parasitaemia. After adjusting for covariates only age <20 years was associated with placental parasitaemia.
Peripheral blood parasitaemia in the women was associated with anaemia (PCV≤30%) lower mean hematocrit (P < .0001). lower
mean birth weight (P < .001) and a higher proportion of low birth weight babies (LBW), (P = .025). Conclusion. In Nigeria,
maternal age <20 years was the most important predisposing factor to malaria at parturition. The main impacts on pregnancy
outcome were a twofold increase in rate of maternal anaemia and higher prevalence of LBW.
Copyright © 2009 Olugbenga A. Mokuolu et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
Falciparum malaria in pregnancy is an important cause of
maternal and perinatal morbidity and mortality in malaria
endemic areas. In pregnancy, malaria is more common,
more severe, more atypical, and more fatal [1]. Pregnant
women in malarious areas may experience a variety of
adverse consequences from malaria infection including
anemia and placental accumulation of parasites while their
newborns may have low birth weight (LBW) from prema-
turity and intrauterine growth retardation (IUGR). Other
consequences of malaria during pregnancy for the newborn
include congenital infection and increased infant mortality
(IM) linked either to preterm-LBW or IUGR-LBW [2, 3].
The occurrence of these problems underscores the impor-
tance of malaria prevention in pregnancy [1, 4]. Intermittent
preventive therapy (IPT) with sulfadoxine-pyrimethamine
(SP) has been shown to be superior to chemoprophylaxis or
case management in the prevention of malaria in pregnancy
[5]. Several other studies have also shown IPT with SP to be
highly efficacious and superior to chloroquine prophylaxis
[6–8]. The WHO currently recommends a three-prong
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approach to the control of malaria during pregnancy. These
are IPT with SP, ITN and effective case management of
clinical infection [9].
In Nigeria, several studies focusing on malaria in the
peripartum period have been conducted but with small
sample sizes and variable findings [10–15]. For instance
one study concluded that although malaria parasitaemia is
prevalent in our locality, the effects on maternal and fetal
wellbeing are comparable in aparasitaemic pregnant women
[15] while another study from a similar geographical area
in the country concluded that congenital malaria is not
uncommon in Lagos nowadays [16]. Mukhtar et al. [16]
also reported relatively high rates of maternal, placental and
cord blood parasitaemia. Based on these findings the authors
recommended that babies born to mothers with malaria
should be screened for congenital malaria. The differences
in conclusions of these studies may be due to the limited
power of the studies owing to their relatively small sample
sizes and their restriction to a small section of a large and
diverse country such as Nigeria.
With the advent of the Global Fund to fight against
Aids, Tuberculosis and Malaria (GFATM), many countries
have been able to receive support for scaling up interven-
tion programmes on malaria control including malaria in
pregnancy. These activities call for better appraisal of the
baseline characteristics of malaria in order to allow for
proper impact assessment of the various interventions. Our
study was therefore undertaken to evaluate the current status
of peripartum malaria and its impact on birth outcomes
in Nigeria. This is to serve as a baseline for Nigeria haven
only recently developed guidelines for malaria prevention in
pregnancy using IPT and ITNs [17].
2. Methods
2.1. Study Locations. The study was conducted in four geo-
political zones of Nigeria, namely North Western (Kaduna),
North Central (Ilorin), South Western (Ibadan) and South
Eastern zones (Enugu) between April 2003 and March 2004.
Malaria is endemic and transmission perennial in all study
sites. Detailed description of the study sites have been
reported by Falade et al. [18].
2.2. Study Population. The subjects of the study were
mothers and their newborn babies delivered at the study
centres within the study period. In addition to willingness
to provide written informed consent, continuous residence
within contiguous areas of study the centre for at least 2 years
and delivery of a life infant were additional inclusion criteria.
3. Study Design
3.1. Sampling Method. This study was prospective and
descriptive with enrolment of every consecutive delivery
fulfilling the inclusion criteria. However to allow for a
representative spread of the subjects across the recruitment
period, enrolment was spread out over a twelve calendar
month period from April 2003 to March 2004. Monthly
recruitment was performed to ensure that mother-baby pairs
were enrolled during both high and low malaria transmission
season in order to determine the seasonal trends in the
prevalence of malaria. Further details of the methodology of
this study is in the report by Falade et al. [18].
3.2. Procedure. Mother and neonate pairs were enrolled from
the labour and delivery unit of each study center. Relevant
maternal and neonatal demographic and clinical charac-
teristics were recorded in case record forms. Clinical data
obtained include details of labour and delivery, anthropo-
metric parameters of the baby and gestational age. In view of
the fact that the subjects were recruited at or near parturition,
they could not be placed on Intermittent Preventive Therapy
(IPT) using Sulfadoxine-pyrimethamine. Specific note was
however made of any malaria preventive measures used by
the subjects.
3.3. Laboratory Procedure. At delivery, thick and thin blood
smears were prepared from maternal finger pricks, placental
aspirates (within 1 hour of delivery) and baby heel pricks
(within four hours of delivery) after initial cardiopulmonary
stabilization. The placental aspirate has been previously
reported to have a good correlation with wedge biopsy
of the placenta [19]. Blood smears were air dried and
subsequently stained with 10% freshly prepared Giemsa stain
at Ph 7.2. The stained smears were examined under ×100
oil immersion lens of a light microscope. Malaria diagnosis
was based on identification of asexual stages of Plasmodium
species on the thick blood film while thin smears were used
for specie identification. Parasite density was determined by
counting the number of parasites against 200 leukocytes (or
500 WBC if no parasite is found) on the thick blood film and
converted to parasites/μL using an assumed total white blood
cell count of 8000 μL [20]. The packed cell volume (PCV) was
determined using blood collected into heparinized capillary
tubes and spun with a Hawksley micro-hematocrit centrifuge
for 5 minutes.
3.4. Quality Assurance. A procedure manual was produced
before study initiation to standardize methodology at all
study sites. Baseline training for microscopists and inves-
tigators was done. A pilot study was also conducted to
evaluate the study process and detect potential site specific
problems in order to harmonize the study protocol. Prestudy
and mid study (within 3 months) quality assurance of
the slides were done in a national reference laboratory.
Continuous quality control on a monthly basis was also
done, by randomly selecting 10 slides for comparison in the
institution’s main laboratory by a consultant haematologist
or the chief technologist.
3.5. Ethical Approval. All centres involved in the study
have Federal Wide Assurance (FWA) certification. Eth-
ical approval was provided by the Joint University of
Ibadan/University College Hospital Ethical Review Board
(Ibadan), the University of Ilorin Ethical Review Committee
(Ilorin), Ahmadu Bello University Ethical Review Board
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(Kaduna) and University of Nigeria Teaching Hospital Enugu
Institutional Review Committee. In addition, ethics approval
was obtained from the Boston University Institutional
Review Board. Written informed consent was obtained
from each study volunteer or from the study participant’s
mother or legal guardian (spouse or grandmother) for study
volunteers under 18 years of age. Continuous ethical review
was carried out for each year the study was active.
3.6. Data Collection and Management. Data was collected
and recorded into precoded case record forms. The com-
pleted case record forms were cross-checked for errors and
missing variables by the supervisor. Thereafter, the data
was entered into the computer by two data entry clerks
using EPI-INFO 6d (Centre for Disease control, Atlanta,
USA) programmed with appropriate CHECK commands to
minimize error during data entry.
Relationships between continuous independent variables
(e.g., age, anthropometric measurements, temperature, and
placental weight) and the outcome variables were tested
using the Student’s t-test or the ANOVA where the assump-
tions were met. Association between categorical variables
was tested using the Chi-square test or Fishers’ exact test
where applicable. For significant associations, the odds ratio
(OR) and the 95% confidence interval (CI) were computed
to determine the association between a risk factor and
particular categorical outcome variable. For all statistical
analysis a P-value less than .05 was considered significant.
For the purpose of this study the following definitions
were applied.
Low Birth Weight. Baby with birth weight less than 2500 g.
Preterm Baby. Any baby delivered before 37 weeks of
gestation. The last menstrual period (LMP) was used for
assessing the gestational ages. However this was validated
with either the first trimester ultrasound assessment of the
gestational age or the Ballard chart. Any discrepancies in
excess of 2 weeks of the gestational age by LMP resulted in
the exclusion of the subject.
4. Results
4.1. Study Population. A total of 2500 subjects were recruited
from the four study centres. However due to the problems
with buffering conditions for Giemsa stain and resulting
deterioration of the blood smears at the Enugu research
center, blood smears could not undergo quality assurance
procedure. All mother-baby pairs enrolled at that site were
excluded from analysis leaving the final sample size analyzed
in this report at 1875 mother-baby pairs.
The majority, 1369 (73%), of the women had no previous
history of abortion while 18% of the women had experienced
at least one episode of abortion prior to the index pregnancy
and 2.5% had had between 2-3 previous abortions. The
women enrolled in the study were aged between 14–50 years.
The distribution of the age, parity and pregnancy outcome
is shown in Table 1. Approximately a third of the pregnant
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Figure 1: Distribution of peripheral parasitaemia in Nigerian
women.
women were primiparous. The overall prevalence of LBW
babies was 6.8%. There was however a significant reduction
in the proportion of LBW babies with increasing parity (P =
.026). The proportion of preterm deliveries was 10% and it
was not associated with parity.
4.2. Prevalence and Risk Factors for Maternal Parasitaemia
4.2.1. Prevalence. Of the 1875 women, there were a total of
404 (maternal and placental) positive smears, thus giving
a peripartum prevalence of malaria of 21.6%. Those with
positive peripheral smears were 319 (17%) while those with
positive placental smears were 267 (14.2%). On the basis of
the detection of parasites in either peripheral blood or the
placenta, 27.2% of primigravidae, 17.9% of secundigravi-
dae, and 19.4% of multigravidae had peripartum malaria
parasitaemia. These differences were statistically significant
(Table 1).
4.2.2. Maternal Age. Figure 1 shows the distribution of
parasitaemia by maternal age. There was a steady decline in
the prevalence of parasitaemia with age from an average of
about 35% in those less than 25 years to an average of 15%
in women 40 years and older. Maternal age less than 20 years
was also significantly associated with both peripheral (P =
.016; OR = 2.3: 95% CI = 1.2–4.9) and placental parasitaemia
(P = .01; OR = 2.6: 95% CI = 1.2–5.4).
4.2.3. Parity. There was also a significant decrease in the
prevalence of peripheral and placental parasitaemia with
increasing parity (P = .0001 in both instances). In each case
these differences were most significant between primiparous
and multiparous women (women in their 2nd pregnancy and
above) (Table 2).
4.2.4. Multivariate Analysis. A linear regression of the age
of the women and parity against maternal parasitaemia
(peripheral and placental) however showed only the age of
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Table 1: Characteristics of the study population, pregnancy outcome and malaria status.
All women
Number of pregnancies
P-value∗∗
1 2 ≥3
No. of women 1875 604 457 814
Percentage 100% 32.2% 24.4% 43.4%
Age in years
Mean ± SD 29.0± 5.1 25.7± 4.0 28.0± 3.8 32.1± 4.6 .0001+
Malaria Status
% Peripheral blood 17.0 21.7 14.0 15.3 .001∗
% Placental blood 14.2 18.4 11.4 12.8 .002∗
Total % malaria positive# 21.6 27.2 17.9 19.4 <.001∗
Mean parasite density (/μL) in
peripheral blood ±SD 456± 5563 783.8± 5873 494.1± 8773 191± 1552 NS
Mean parasite density (/μL)
placenta ±SD 1093± 15321 1504± 17589 985± 18470 847± 10950 NS
Delivery outcome
% Low birth weight 6.8 8.9 6.8 5.3 .026∗
% Preterm delivery 10.0 9.3 10.1 10.5 .71∗
+Wilcoxon rank-sum test; ∗Chi-squared test; #Parasites were detected in the peripheral and/or placental blood.
∗∗Comparisons were between the three categories of number of pregnancies.
the women was significantly associated parasitaemia in the
women (the contributions were t = 3.27; P = .001 for age:
t = −0.75; P = .45 for parity).
4.3. Effect of Parasitemia on Maternal and Babies Hematocrit.
The mean (SD) haematocrit of the women with patent
parasitaemia was 34% ± 5.0 while that for those without
patent parasitaemia was 37%±5.4 (F-stat = 46.4, P = .0001).
4.3.1. Maternal Anaemia. Maternal parasitaemia was
strongly associated with anaemia in the mothers. The
presence of patent parasitaemia; peripheral, placental
or combined placental/peripheral, had a twofold risk of
resulting in significant maternal anaemia (hematocrit
≤30%). When this was stratified by parity there was
no significant difference in the mean haematocrit of
primigravidae with positive parasitaemia and multigravidae
with positive parasitemia (Tables 3 and 4).
4.3.2. Babies’ Mean Haematocrit. Peripheral and placental
parasitaemia in the women did not affect the mean haemat-
ocrit of the babies (Tables 3 and 4).
4.4. Effect of Parasitaemia on Pregnancy Outcome
4.4.1. Birth Weight. There was discordance with respect
to peripheral and placental parasitaemia on the babies’
birth weight. The observed significant differences were with
respect to peripheral parasitaemia. Peripheral parasitaemia
was associated with significantly lower mean birth weight
3077 g ± (523) versus 3175 g ± (477) among babies born
to mothers with patent peripheral parasitemia and those
without; F-stat = 10.7, P = .001. Low birth weight (LBW)
occurred in 128/1875 deliveries thus giving a prevalence
of 6.8%. Peripheral parasitaemia was also significantly
associated with LBW babies (31/311 [9.97%] versus 97/1556
[6.2%]; P = .025, OR = 1.6 [1.1–2.5]).
4.4.2. Other Outcomes. In contrast, preterm deliveries and
Apgar scores at 1 and 5 minutes were not associated with
peripheral parasitaemia in the mother.
5. Discussion
In this study, we found that 21% of mothers had peripheral
(maternal) and/or placental parasitaemia at parturition.
Previous studies from Nigeria reported parasitaemia rates
among pregnant women or at parturition ranging from
24.8–80% [15, 21–25]. Studies from other malaria endemic
parts of Africa have also reported large variations in the
occurrence of malaria parasitaemia among the pregnant
women. For instance, in Cameroon; Walker-Abbey et al.
[26] reported a prevalence of 82.4% while Tako et al. [27]
reported a total malaria positivity rate of 21.5%. The wide
ranges in reported prevalence of malaria may be due to
multiple factors. One factor is the method of diagnosis. The
studies that reported very high rates, that is, >70%, were
those that involved the use of PCR for parasite detection.
In one of such studies with 82% prevalence, only 27.5%
were detectable by microscopy while parasitaemia was sub-
microscopic in over 50% [26]. Other factors that may
explain this variation include intensity of transmission, study
population characteristics (age, parity, HIV status), use of
preventive measures (e.g., IPT, ITNs), and study design.
Many studies had small sample sizes and were restricted to
just a single site. This was a multicentre study across the
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Table 2: Risk factors for peripartum parasitaemia among parturient mothers in Nigeria.
Characteristics Parasitaemia
positive
Parasitaemia
negative
n P OR (95% CI)
Peripheral blood
Maternal age <20 years 11 (32.4) 23 (67.6) 1875 .016 2.3 (1.2–4.9)
Maternal age ≥20 years 308 (16.7) 1533 (83.3)
Placental
Maternal age <20 years 10 (29.4) 24 (70.6) 1875 .01 2.6 (1.2–5.4)
Maternal age ≥20 years 257 (14.0) 1584 (86.0)
Peripheral blood
Primiparous 131 (21.7) 473 (88.3) 1875 .0001 1.5 (1.2–2.0)
Multiparous 188 (14.8) 1083 (85.2)
Placental
Primiparous 111 (18.4) 493 (81.6) 1875 .0001 1.6 (1.2–2.1)
Multiparous 156 (12.3) 1115 (87.7)
Table 3: Effect of maternal parasitaemia on mean hematocrit and
neonatal birth weight.
Parameter Parasitaemia maternal
P-value
Mean (±SD) Positive Negative
Maternal HCT (%) 34.3 (±5.1) 36.5 (±5.4) .0001
Babies’ HCT (%) 52.3 (±7.9) 52.6 (±8.3) .663
Birth weight (g) 3078 (±523) 3175 (±477) .001
major geographic and ecological zones of Nigeria and would
therefore be expected to be more representative of the true
situation of malaria at parturition in the country. To the
best of the authors’ knowledge this is the largest study of
a multicentre dimension to be conducted on peripartum
malaria in Nigeria.
In this study, parasitaemia at the time of delivery was
found to be associated with low parity and maternal age.
Several other studies have reported similar associations [27–
29]. A multivariate analysis however revealed that only
the age of the women less than 20 years was significantly
associated with parasitaemia in the women. This finding
was also described by Tako et al. [27] and Saute et al.
[29]. In both of these studies multivariate analysis found
that younger maternal age, (teens to less than 25 years),
was significantly associated with placental parasitaemia after
adjusting for confounding variables like parity. The authors
observed that younger but not older first time mothers were
more likely to have placental malaria [27] or peripheral blood
malaria [29]. In the light of this finding Tako et al. [27]
suggested that pregnancy-associated immunity and naturally
acquired immunity may differ among women in Yaounde´,
Cameroon. The hypothesis was that the development of
pregnancy associated immunity, for example, production of
antibodies that inhibit adherence of placental parasites to
chondroitin sulphate A, may be very important in women
<25 years of age who have lower levels of acquired immunity.
While older women living in such endemic areas may have
obtained adequate immunity following repeated exposures
to eliminate any infecting malaria parasite and are thus less
dependent on anticytoadherent antibodies [27]. Whereas
this hypothesis is plausible, it is not certain whether it will
also explain the fact that the observed relationship is not
limited to only placental parasitaemia since the same was true
for parasitaemia in the maternal peripheral blood.
Parasitaemia in the mothers was found to be significantly
associated with lower maternal hematocrit. This finding is
not unexpected as the association of malaria in pregnancy
and low hematocrit has been recognized and reported by
previous workers [14, 30]. The drop in hematocrit occurs as
a result of the fact that parasitized and unparasitized erythro-
cytes are destroyed by the spleen during malaria infection. It
is however known that using drugs that are normally effective
against malaria within a locality significantly reduces the
occurrence of this anaemia [31].
The main effect of maternal parasitaemia on the babies is
the reduction in the birth weight. This is consistent with the
observations from other malaria endemic countries [32–35].
Considering that a needle aspiration technique was applied
for placenta parasite detection, it was not possible, in this
study, to distinguish between acute and chronic stages of the
placental infection. The impact of malaria during pregnancy
on LBW in sub-Sahara Africa has been extensively reviewed
[36, 37]. It has been estimated that in areas where malaria is
endemic, about 19% of LBW infants are due to malaria and
6% of infant deaths are due to LBW caused by malaria. These
estimates imply that around 100 000 infant deaths each year
could be due to LBW caused by malaria during pregnancy in
areas of malaria endemicity in Africa [37].
The observed impact of malaria on the mother and their
newborns add justification for promoting use of malaria
preventive measure in pregnancy. The tools for achieving
effective malaria control are now available; these include use
of ITNs, IPT, and effective treatment. The use of these tools is
also being facilitated with the recent production of a number
of treatment guidelines and policy documents [17, 38, 39].
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Table 4: Relationship between parasitaemia and anaemia in the mothers.
Maternal
parasitaemia
Anaemia No anaemia n P OR (95% CI)
Peripheral and
placental blood
Positive 47 (25.8) 135 (74.2) 1875 .0001 2.1 (1.4–2.9)
Negative 244 (14.5) 1439 (85.5)
Peripheral blood
Positive 79 (24.8) 240 (75.2) 1875 .0001 2.1 (1.5–2.8)
Negative 212 (13.7) 1334 (86.3)
Placental blood
Positive 66 (24.7) 201 (75.3) 1875 .0001 2.0 (1.5–2.7)
Negative 225 (14.1) 1373 (85.9)
In the present study the level of use of malaria preventive
measures was generally low. It is essential that all stakeholders
combine efforts to ensure successful implementation in
the deployment of these various tools in order to achieve
a reduction in the burden of malaria in pregnancy in
Nigeria.
6. Conclusions
In Nigeria, 1 in every 5 women has malaria (maternal and/
or placental) parasitaemia at delivery. Maternal age less
than 20 years was the most important predisposing factor.
Maternal anaemia, reduction in maternal hematocrit, mean
birth weight and a higher proportion of LBW babies were
the major deleterious outcomes of malaria in the peripartum
period. The findings of this large multicentre study which
recorded a prevalence of 21.6% for patent parasitaemia
(mother and/or placenta) underscores the need for a focused
and concerted effort to address the control of malaria during
pregnancy in Nigeria.
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